文献速递前列腺癌男科与性医学

二甲双胍对前列腺癌患者发病率、复发率和死亡率的影响:整合真实世界研究证据

Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-07-16

该Meta分析检索10个电子数据库和4个注册库,评估二甲双胍对前列腺癌临床结局的影响。结果显示二甲双胍使用与前列腺癌发病率降低相关(RR 0.82,95%CI 0.74-0.91),与复发率(RR 0.97,95%CI 0.81-1.15)和死亡率(RR 0.94,95%CI 0.81-1.09)无显著关联,且保护效应与用药时长呈线性相关。

要点

  • 二甲双胍使用与前列腺癌发病率降低独立相关(RR 0.82,95%CI 0.74-0.91)。
  • 二甲双胍使用与前列腺癌复发率(RR 0.97,95%CI 0.81-1.15)无显著关联。
  • 二甲双胍使用与前列腺癌死亡率(RR 0.94,95%CI 0.81-1.09)无显著关联。

核心结论

  • 二甲双胍使用与前列腺癌发病率降低独立相关,且该效应与用药时长相关;二甲双胍使用与前列腺癌复发率和死亡率均无显著关联。

研究设计与样本

  • 系统检索10个电子数据库和4个注册库,采用随机效应模型合并相对危险度(RR)及95%置信区间(CI),并进行亚组分析和敏感性分析。

主要发现

  • 二甲双胍使用与前列腺癌发病率降低相关(RR 0.82,95%CI 0.74-0.91)。
  • 二甲双胍使用与前列腺癌复发率降低相关,但未达统计学显著(RR 0.97,95%CI 0.81-1.15)。
  • 二甲双胍使用与前列腺癌死亡率无显著关联(RR 0.94,95%CI 0.81-1.09)。
  • 亚组分析显示,研究类型为队列研究且人群来自亚洲和欧洲时,服用二甲双胍可降低前列腺癌发病率。
  • 二甲双胍使用时长与其保护效应之间存在线性相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metformin has been suggested to reduce the risk of cancer. However, previous studies have been inconsistent regarding the relationship between metformin use and the risk of occurrence of prostate cancer (PCa). The purpose of this study was to assess the effect of metformin on clinical outcomes in patients with PCa in a meta-analysis and to explore the possible dose-response relationship. METHODS: A systematic literature search was conducted in 10 electronic databases and 4 registries. The combined relative risks (RRs) were calculated using a random-effects model with 95% confidence interval (CIs) to assess the effect of metformin on the risk of PCa. Relevant subgroup analyses and sensitivity analyses were performed. RESULTS: The across studies results show that metformin use associated with lower incidence of PCa (RR: 0.82, 95% CI: 0.74-0.91). Metformin use was also found to reduce PCa recurrence, but the results were not statistically significant (RR: 0.97, 95% CI: 0.81-1.15). Metformin use was not associated with PCa mortality (RR: 0.94, 95% CI: 0.81-1.09). The results of subgroup analyses indicated that the type of study was a cohort study and the population came from both Asia and Europe showed that taking metformin reduced the incidence of PCa. A linear correlation was found between the duration of metformin use and its protective effect. CONCLUSIONS: This meta-analysis revealed an independent correlation between metformin use and reduced incidence of PCa. Metformin use was not associated with either PCa recurrence rate or mortality. Furthermore, the effect of metformin on PCa incidence was found to be related to duration.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Liu Y, Zhang Q, Huang X, et al. Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies. Prostate Cancer Prostatic Dis. 2024. PMID: 39014063. doi:10.1038/s41391-024-00871-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。